ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARQT Arcutis Biotherapeutics Inc

8.985
0.045 (0.50%)
Last Updated: 12:57:18
Delayed by 15 minutes

Period:

Draw Mode:

Volume 701,876
Bid Price 8.98
Ask Price 8.99
News -
Day High 9.295

Low
1.76

52 Week Range

High
15.21

Day Low 8.86
Company Name Stock Ticker Symbol Market Type
Arcutis Biotherapeutics Inc ARQT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.045 0.50% 8.985 12:57:18
Open Price Low Price High Price Close Price Prev Close
9.02 8.86 9.295 8.94
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,857 701,876 $ 9.04 $ 6,346,062 - 1.76 - 15.21
Last Trade Time Type Quantity Stock Price Currency
12:57:58 200 $ 8.985 USD

Arcutis Biotherapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
865.51M 96.81M - 59.61M -262.14M -2.71 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Arcutis Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARQT Message Board. Create One! See More Posts on ARQT Message Board See More Message Board Posts

Historical ARQT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.01510.388.4359.522,580,539-1.03-10.28%
1 Month9.3913.178.43510.532,998,679-0.405-4.31%
3 Months5.9213.175.389.414,345,2793.0751.77%
6 Months2.5213.171.765.734,770,8396.47256.55%
1 Year13.9715.211.766.173,065,626-4.99-35.68%
3 Years30.5836.451.769.151,333,442-21.60-70.62%
5 Years23.0540.881.7610.20995,744-14.07-61.02%

Arcutis Biotherapeutics Description

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Your Recent History

Delayed Upgrade Clock